Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03201094 · ClinicalTrials.gov registry record · NA

Impact of NMES and HPRO on Recovery After SAH- Pilot Study

A NA study of Inflammation and Subarachnoid Hemorrhage, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03201094: Recruiting NA study of Inflammation and Subarachnoid Hemorrhage, sponsored by University of Maryland, Baltimore.

NCT03201094 is a NA study of Inflammation and Subarachnoid Hemorrhage that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 30 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03201094, a NA study of Inflammation and Subarachnoid Hemorrhage, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The study purpose is to investigate the hypothesis that in adults with SAH, early neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls receiving standard of care interventions for nutrition and mobilization. The investigators will accomplish this by studying the effects of a high protein (HPRO) nutritional treatment as well as NMES intervention have upon muscle wasting and motor strength acutely after SAH. This will be addressed in a prospective trial of SAH patients receiving HRPO with NMES as compared to age and severity-matched SAH patients undergoing standard of care interventions for nutrition and mobilization. Additionally, the study will investigate the impact HPRO and NMES interventions have upon inflammatory cytokines and markers of energy balance. Results of this study will establish evidence for precision nutrition plus early exercise to mitigate the catabolic and inflammatory state produced by SAH to improve muscle, metabolic, and health recovery outcomes.

Primary Outcome

Change in the muscle layer thickness of the quadriceps muscle as measured by ultrasound.

Conditions Studied

Inflammation Subarachnoid Hemorrhage Muscle Atrophy Nutritional and Metabolic Disease

Interventions

  • DEVICE Neuromuscular Electrical Stimulation (NMES)
  • DIETARY_SUPPLEMENT High Protein Supplementation

Study Locations (1)

Maryland

  • University of Maryland Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-12-01
Est. Completion 2026-10-30
Phase NA
University of Maryland, Baltimore

560 total trials

What NCT03201094 shows while recruiting

NCT03201094 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (90% lower).

The record links to 4 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Neuromuscular Electrical Stimulation (NMES) is the first listed.

NCT03201094 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT03201094 about?

NCT03201094 is a clinical study titled "Impact of NMES and HPRO on Recovery After SAH- Pilot Study". The study purpose is to investigate the hypothesis that in adults with SAH, early neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls receiving standard of care intervent...

What is the current status of trial NCT03201094?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2017-12-01. Estimated completion is 2026-10-30.

What conditions does trial NCT03201094 study?

This clinical trial studies the following conditions: Inflammation, Subarachnoid Hemorrhage, Muscle Atrophy, Nutritional and Metabolic Disease.

What interventions are being tested in trial NCT03201094?

The interventions under investigation include: Neuromuscular Electrical Stimulation (NMES) (DEVICE), High Protein Supplementation (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03201094?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03201094 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03201094's enrollment target sits among peer trials

30 98th of 132 higher than 27 of 132 other Inflammation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03201094

Source: ClinicalTrials.gov NCT03201094, the US trial registry maintained by the National Library of Medicine. NCT03201094 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.